<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02078674</url>
  </required_header>
  <id_info>
    <org_study_id>FLU-MI7A-201</org_study_id>
    <nct_id>NCT02078674</nct_id>
  </id_info>
  <brief_title>A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant</brief_title>
  <official_title>A Phase I/II Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Anhui/1/13 (H7N9) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Adults With and Without Matrix-M1™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novavax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Novavax</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, observer-blinded, placebo-controlled trial in adults 18 to 64 years&#xD;
      old. Randomization will be stratified by age (18 to 49 years and 50 to 64 years) and by prior&#xD;
      influenza immunization within the past three months. Subjects 18 to 49 years of age will&#xD;
      comprise ~67% of subjects in each treatment group, and the balance will comprise subjects 50&#xD;
      to 64 years.&#xD;
&#xD;
      Each subject will receive two identical IM doses of test article at a 21-day interval (Day 0&#xD;
      and Day 21), in alternate deltoids. For each subject, study follow-up will span approximately&#xD;
      385 days total, or approximately 13 months from the first dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Safety</measure>
    <time_frame>Day 0 to Day 384</time_frame>
    <description>Counts (and percentages) of subjects with solicited local and systemic AEs over the seven days post-injection and all adverse events, solicited and unsolicited, including adverse changes in clinical laboratory parameters, over 42 days post-first injection.&#xD;
In addition, MAEs, SAEs, and SNMCs will be collected for one year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity as assessed by hemagglutination-inhibiting (HAI) antibody titers against the vaccine-homologous A/Anhui/1/13 (H7N9) virus.</measure>
    <time_frame>Day 0 to Day 384</time_frame>
    <description>Geometric mean titer (GMT) Geometric mean ratio (GMR) Seroconversion rate (SCR) Seroresponse rate (SRR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as assessed by neuraminidase-inhibiting antibodies to N9.</measure>
    <time_frame>Day 0 to Day 384</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">610</enrollment>
  <condition>Influenza (Pandemic)</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Avian Influenza VLP (H7N9)</intervention_name>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Matrix-M1™ adjuvant</intervention_name>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult male or female, 18 to 64 years of age,&#xD;
&#xD;
          2. Willing and able to give informed consent prior to study enrollment,&#xD;
&#xD;
          3. Able to comply with study requirements, and&#xD;
&#xD;
          4. Women of child-bearing potential must have a negative urine pregnancy test prior to&#xD;
             each vaccination, and will be advised through the Informed Consent process to avoid&#xD;
             becoming pregnant over the duration of the study, and must assert that they will&#xD;
             employ an effective form of birth control for the duration of the study. Acceptable&#xD;
             forms of birth control are: credible history of continuous abstinence from&#xD;
             heterosexual activity or prior surgical sterilization, hormonal contraceptives (oral,&#xD;
             injectable, implant, patch, ring), barrier contraceptives (condom or diaphragm), and&#xD;
             intrauterine device (IUD). Women with an adequately documented history of surgical&#xD;
             sterility, or ≥50 years of age and without menses for ≥1 year are exempt from urine&#xD;
             pregnancy testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded if they meet any of the following criteria:&#xD;
&#xD;
          1. Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care.&#xD;
&#xD;
               -  Asymptomatic conditions or findings (e.g., mild hypertension, dyslipidemia) that&#xD;
                  are not associated with evidence of end-organ damage are not exclusionary&#xD;
                  provided that they are being appropriately managed and are clinically stable&#xD;
                  (i.e., unlikely to result in symptomatic illness within the time-course of this&#xD;
                  study) in the opinion of the Investigator.&#xD;
&#xD;
               -  Acute or chronic illnesses or conditions which may be reasonably predicted to&#xD;
                  become symptomatic if treatment were withdrawn or interrupted are exclusionary,&#xD;
                  even if stable.&#xD;
&#xD;
               -  Note that illnesses or conditions may be exclusionary, even if otherwise stable&#xD;
                  and clinically minor, due to therapies used to treat them (see exclusion criteria&#xD;
                  3, 5, 8, 9).&#xD;
&#xD;
          2. Any grade 1 or higher (as based on the Toxicity Grading Scale [TGS]) abnormality in&#xD;
             ALT, AST, alkaline phosphatase, total bilirubin, blood urea nitrogen, or creatinine&#xD;
             levels.&#xD;
&#xD;
          3. Any grade 2 or higher (as based on the TGS) vital sign or clinical laboratory&#xD;
             abnormality not specified in criterion 2 above. Note that any abnormal vital sign may&#xD;
             be repeated at the Investigator's discretion.&#xD;
&#xD;
          4. Participation in research involving investigational product (drug / biologic / device)&#xD;
             within 45 days before planned date of first vaccination.&#xD;
&#xD;
          5. History of a serious reaction to prior influenza vaccination.&#xD;
&#xD;
          6. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza&#xD;
             vaccine.&#xD;
&#xD;
          7. Received any vaccine in the 4 weeks preceding the study vaccination; or any A(H7N9)&#xD;
             avian influenza vaccine at any time.&#xD;
&#xD;
          8. Any known or suspected immunosuppressive condition, acquired or congenital, as&#xD;
             determined by history and/or physical examination.&#xD;
&#xD;
          9. Chronic administration (defined as more than 14 continuous days) of immunosuppressants&#xD;
             or other immune-modifying drugs within 6 months prior to the administration of the&#xD;
             study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a&#xD;
             systemic dose ≥10mg of prednisone per day or equivalent. The use of topical, inhaled,&#xD;
             and nasal glucocorticoids will be permitted.&#xD;
&#xD;
         10. Administration of immunoglobulins and/or any blood products within the 3 months&#xD;
             preceding the administration of the study vaccine or during the study.&#xD;
&#xD;
         11. Acute disease at the time of enrollment (defined as the presence of a moderate or&#xD;
             severe illness with or without fever, or an oral temperature &gt;38.0°C on the planned&#xD;
             day of vaccine administration).&#xD;
&#xD;
         12. Known disturbance of coagulation.&#xD;
&#xD;
         13. Women who are pregnant or breastfeeding, or plan to become pregnant during the study.&#xD;
&#xD;
         14. Suspicion or recent history (within one year of planned vaccination) of alcohol or&#xD;
             other substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. Nigel Thomas, Ph. D.</last_name>
    <role>Study Director</role>
    <affiliation>Novavax, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research, Inc.</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>March 3, 2014</study_first_submitted>
  <study_first_submitted_qc>March 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <disposition_first_submitted>September 20, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>September 20, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 23, 2016</disposition_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>H7N9</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

